Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
PapaJohn pays .1742! Scalped him good this time!
GLJPJ!
§
$GNOW 386KK @ .26
Fingers crossed!
§
How about when they announce the collaboration in Retts ind? Think it will run then?
Out @ .32 578% core, 368% average.
4,687,833 traded
$234,585 GP
§
A perfect double run!!! §
You've been to many meetings in an attorney's office where they weren't present?
I wanted to edit this post to include a couple of full text articles that I could not locate initially.
First, a very important NIH publication:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2907736/
Second, a similar paper highlighting the work of Dr Fisher that led to the discovery of A3-71:
https://www.researchgate.net/publication/5765600_Muscarinic_acetylcholine_receptors_and_CNS_drug_targets_Pharmacol_Ther
---------------------------------
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=122652549
plexrec: Being well informed helps with the anxieties, my pleasure.
An absence/lessening in cholinergic side effects is likely crucial to the approval outcome, and would require extensive PK analysis. The AU hype may be of great interest to schizophrenia researchers, as well.
§
But but but...they have no lab!
"The study was sponsored and performed by Libor Velisek, MD, PhD, Professor of Cell Biology & Anatomy, Pediatrics, and Neurology and his laboratory at New York Medical College (NYMC)."
§
Retts, West and Dravet syndromes. Devastating juvenile epilepsy disorders.
Dr French just finished her work on the Novartis trial.
'"I have to emphasize to you what a big leap this is," Jacqueline French, MD, professor, neurology and co-director, epilepsy research and epilepsy clinical trials, NYU Comprehensive Epilepsy Center, New York, told Medscape Medical News.
"Up until now, we have not treated anybody for their epilepsy; we have only treated them for their seizures. We have given them drugs that suppress their seizures, but we have not fundamentally changed the mechanism underlying that, which caused the epilepsy."'
http://www.medscape.com/viewarticle/862306
What could be next?
"I am extremely impressed with the positive preclinical epilepsy data for ANAVEX 2-73, which demonstrates a significant reduction in anti-seizure efficacy relative to three currently approved epilepsy drugs as well as significant synergy with each of these drugs. Additionally, ANAVEX 2-73 was shown to be safe in a Phase 1 human trial, which is critical to next-general epilepsy therapies,” said Dr. French. “I look forward to collaborating with Anavex and its impressive team of scientific advisors as we work to further develop ANAVEX 2-73."
http://www.anavex.com/?news=anavex-appoints-epilepsy-and-clinical-trial-methodology-expert-to-scientific-advisory-board
§
$INNV YUP! AN EASY .24 THIS WEEK!!!! DOLLARS SOON!!! $INNV
Is that how you do it?
§
$SIAF cover and turn @ 4.60
Easy money!
§
nannynannybooboo §
Why? Oh, I see...you're all done spamming it up?
http://investorshub.advfn.com/boards/profile.aspx?user=228888
"Excuse me sir, can ya step up onto the curb? I gotta sweep the gutter here...parade ended a while ago"...???
§
$INNV Awesome second helping!
600KK .0857 X .0137
This one is a keeper for a while!
§
Congrats seventhwave! I'll toss you a free month in June.
PDP is a great comparison. Balance sheet is better...right now. I think the market segment and sales channels are better in the other, though. Did some quick guerilla sales calculations and it looks like product is moving well.
As you can see it's up 30% today with some nice market fluff and volume. And not a peep on the board...sweet!
Sorry to the bag holder's here. Hope we helped you out on the side.
§
Go Team! §
My point exactly. All our scientific exploration could lead us right back to nature and how that can govern our individual diets, based upon genetic, sub-racial, geographic, etc demographics...toward the ideal personal homeostasis.
So today we test the processes with small molecules. Cilantro's pretty awesome...I can never eat enough.
Oh lort, we've become Nutralife this weekend...!
§
Yes, I thought that too, perhaps. It would be conservative and more the CEO's style, not too flashy. Part of the survey impetus!
§
Thank you. I knew you had more to share!
The inflammatory and plasticity components of neurodegeneration appear, certainly, to be an integral part of all cellular apoptosis so it is all a part of the study of how we age and expire.
I think in the future genetic evaluation and dietary paradigms will play a big part in the longevity of the species. It's all there in nature. We just come around to it in a pseudo-scientific molecular chemistry-based way. We'll catch up with mother nature around the time we really need the knowledge to protect our survival.
I would hope we can put these experiments to work, in our general populations. Without fear of how or why we might fail, as the sacrifice we must all make in the search to learn must outweigh the rate at which the failure to do so contributes toward our demise.
Now beer-me please, Cous!
§
Survey for Tuesday May 17, 2016
http://investorshub.advfn.com/boards/board_surveymenu.asp?board_id=11474
Have fun!
§
That is a whole 'nother can of worms.
http://www.ncbi.nlm.nih.gov/pubmed/26404455
http://www.ncbi.nlm.nih.gov/pubmed/15877923
http://www.nature.com/npp/journal/v34/n12/full/npp200984a.html
Please shed more insight into the interaction between linoleic acid and and Anavex's compounds, if you are able.
§
I am sure there will be a premarket PR Tuesday morning. The conference presentation starts at 9:40AM ET. Should be some good fireworks to kick off the day!
A news-pending delay premarket for the day would be a welcome relief from the typical shenanigans. Disturbing data coupled with a P3 and/or collaboration announcement would surely trigger a reg delay. It would be nice to see us drop a bomb for a change, instead of getting the beat-down on good news.
I know Missling is waiting to play that card. This looks like the perfect setup.
"Go get 'em Tiger!"
§
So the focus of the compound development is selective action on Sigma receptors, coupled with selective Muscarinic acetylcholine receptor action, very simply put.
One thing that is evident in reading about the development of our compounds, in so far as the abandoned ones, is the scientists are working from the knowledge of the discoveries of the different types of nerve cells affected by particular M-receptors.Thus, the current pipeline is borne of these very recent discoveries, and I believe that is why Dr Missling and the co have a particular confidence about them.
There is no way to discuss this in a layman's forum without using the science jargon, so everyone sort of needs to read for themselves. Thankfully, Anavex has provided many full-text papers on the website and providing links is the best way to convey the thinking.
Here is a good chart that shows the nerve systems(by disease effect) vs the M-receptors.
This article is good background info when reading the science jargon in the papers.
http://www.guidetopharmacology.org/GRAC/FamilyIntroductionForward?familyId=2
Other good articles for background reading:
(Our compounds are mAChRs)
http://www.sciencedirect.com/science/article/pii/S0929664615001497
https://biosignaling.biomedcentral.com/articles/10.1186/1478-811X-7-20
The patent applications are an important source for the info, as orveko_inc reminded me:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=122484962
Selective affinity for the M1,M4 and M5 receptors appears to be key in the CNSDs. Donepezil's side effects are related to it's effects on the M2 and M3 receptors, found mainly in the GI tract...hence Donepezil's GI side effects. This is why A2-73 can alleviate the side effects of higher doses of donepezil, as it has an opposite effect on the M2&3 (again, very simply put)
My point in all this flirting with you George is that the more I read, the more I realize these guys know all this. And they have crafted these drugs to do exactly what everyone is leaning-towards as being the approach with the most far-reaching implications. That is why we see the selective monotherapy-in-combo approach so often. The Sigma/M-receptor system is like a string instrument...and we are learning to play chords and make music.
Cue Cbd!
Then we have the Sigma-1 effects and their importance on the GPCRs and NMDA. First, important reading from the library:
This one gives insights into A1-41.
http://www.anavex.com/publication/the-pharmacology-of-sigma-1-receptors/
http://www.anavex.com/?news=anavex-encouraged-by-scientific-data-confirming-sigma-1-receptors-beneficial-direct-interaction-with-cannabinoid-receptor
I had read all this stuff, and then I started reading about Heptares.
http://www.heptares.com/publications/
After exploring their info I came to the firm conclusion that Anavex is a bit further ahead in the race, but has yet to sell the development rights to one of it's compounds. There has to be a reason for that. Heptares sold out every step of the way on far less preclinical data on the MOA of it's compounds. Perhaps it is that their compounds, by design, are just incredibly selective in affinity and these BPs believe that's a viable clear-cut pathway. I could not find info on any Sigma Receptor System interactions for HTL9936 and HTL18318. More details needed! Perhaps Anavex just has the right mixed package already discovered. I think Heptares and/or any of their collaborative partners would kill to have A2-73...much less A3-71.
Our other 1xxx series of compounds appear to act on other M-receptors specifically involved with cancer cell growth. Some light reading on that:
http://onlinelibrary.wiley.com/doi/10.1111/j.1471-4159.2009.06396.x/pdf
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3604886/
It's all too much, yet not enough. Comments and corrections are appreciated.
Blessings
§
They do both...and profit twice.
Dear George,
By John, I think you've got it!
https://en.wikipedia.org/wiki/Myristic_acid
https://www.truthinaging.com/ingredients/myristic-acid
http://reallywell.com/myristic_acid.htm
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4827442/http://www.anavex.com/wp-content/uploads/PNAS-2015-Tsai-1422001112-2.pdf
http://www.cell.com/trends/pharmacological-sciences/abstract/S0165-6147%2816%2900004-3
Expect VERY GOOD developments here, in the future!
§
Yeah, that's the one...'ol clueless Cory. I took "interesting" to mean "unusually borrower-friendly for LP".
§
Cory Renauer, ARE YOU FOR REAL!!!???
I believe the estimate was based on the pre-split share count at the 20MM mark, last fall. I had estimated -.24(pre-split) based upon the current 36MM. So -.06 is right on the money...$720,000/month. No big surprise except to CORY!
1: Earnings call? Seriously Cory, those are for companies that have earnings! What's there to discuss? All the necessarily secretive IP, collaborative and clinical data stuff? Yes, the company tells all that bears noting sufficiently via PRs and IR correspondence. Did you email politely?
2: What would keep a potential AD compound who's "Anecdotal results have been incredible" from already being partnered? $$$ BIG BUCKS $$$ maybe, Cory?
3: Dilution...which brings us back to 2:
4: You don't do LinkedIn, Bloomberg and Morningstar very well, do you Cory? "Having so many roles must be exhausting" Yes, and he did a great job in all of them...unlike yourself.
5: OK, I'll give this one some gusto...
*The preclinical work necessary to advance the lead compound(s) has been done. There is no need for a lab right now.
*The company smartly takes advantage of qualified outside services, when appropriate.
*The scientists do have their own lab privileges outside of the company.
*Independent and grant-funded outside conducted studies.
REMARKABLE, ISN'T IT...CORY?
It's OK. Nobody approves of the little orphaned redhead from under the stairs. It's nothing new. She's gonna kick ass!
Good luck...cory
§
Thank you. If you remember, there was some discussion around the time I first posted that chart, 10/22/15 or so, about the timing of data releases during the PART B. Too tired to go look today
Awesome PK/PD link, thanks!
§
As you can see on the chart, CBB & EEG are not done at 26 weeks. So perhaps we will get an interim release for that period without PK analysis, or none at all and it will be reported along with the PK data after 38 weeks.
KarinCA: Oh yes. I guess that's a "not yet":
https://www.nih.gov/news-events/news-releases/hhs-nih-take-steps-enhance-transparency-clinical-trial-results
§
I agree there:
That's what I would say 123tom. Thanks BR
§
The OTC Daily List hit with the info at 1:00ET. The stock dropped on heavy volume, but recovered quite a bit before the close. While, technically, advance notice it is not for the general investing public.
I agree with Dark Force. It worked out good enough that it was easily put-behind. And to compare where we stand now vs if we were still OTC is silly.
I will go ahead and put a chit in the negative column though. It is rather stoopid empty!
§
NDAs and CASs and SECs...oh my!
Can't we just click our heels already?
"There's no place like approved...There's no place like approved"
Would also explain how the 3-71 ODD got released. Different compound, not part of NDA. Strategic moves, not surprising. Terminator.
§
Much appreciated. I do think your point is relevant. I would only counter that the manipulation and damage to a successful uplist that would have occurred, had the co pre-announced the R/S, was the reason for the swiftness.
Uplist to a major exchange was the last item on Missling's list. We were fully expecting and looking forward to it and the intrepid investor knew it could not be accomplished without a corresponding pps adjustment.
It was a well played strategic move, IMO. Water under the bridge, too, anyhow.
§
I agree. Though it is not illegal to just be silent for a period of time for the sake of the business plan, and often advised. There are no mandates about when trial results must be made public, only when they must be submitted to the clintrials.gov registry.
§
We don't have a patent that matches the indication enough to protect it....basically. Meaning it is a matter of the particular IP meeting the proper development stage of the compound for a deal to be struck. So, for instance, we could get a partnership for the epilepsy indication if the clinical development stage meets the IP just put in place:
WIPO Pat App No.WO2016064711
U.S. Prov. Pat. App. No.62/065,833
International Application No.: PCT/US2015/056172
“A19-144, A2-73 and Certain Anticholinesterase Inhibitor Compositions and Method for Anti-Seizure Therapy”
Provisional (ANAVEX 2-73 Method of use, epilepsy)
Having the world app in place provides a measure of protection, just as the Greek protection on the compound provides, I think. Nobody is going to try to steal it while pending.
I think the IP generally works itself out and is not so much a do-or-die situation. Keeping up on it is important to your investment though, IMO.
Again, when I look at Missling and the people he has aligned and (managed to) surround himself with, I don't have a lot of doubt. These people appear to be trying to build something BIG, and that never happens by taking a bunch of easy "outs".
Patience, perspective.
§
The pps rose 200% post split. You had ample time to say "whew" and escape unscathed.
No, just throwing up my own one line garbage post